WEKO3
アイテム
{"_buckets": {"deposit": "e7d3f44e-7d75-45d5-9f76-add1e4974619"}, "_deposit": {"created_by": 4, "id": "304", "owners": [4], "pid": {"revision_id": 0, "type": "depid", "value": "304"}, "status": "published"}, "_oai": {"id": "oai:kawasakigakuen.repo.nii.ac.jp:00000304", "sets": ["34"]}, "author_link": ["372", "314", "376"], "control_number": "304", "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "19", "bibliographicPageStart": "12", "bibliographicVolumeNumber": "1", "bibliographic_titles": [{"bibliographic_title": "COGNITION \u0026 REHABILITATION", "bibliographic_titleLang": "en"}]}]}, "item_10001_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Alzheimer disease (AD) is the most common type of dementia and may account for 60 - 70% of dementia cases. Senile plaques are a hallmark of AD, and their major constituent is amyloid β-protein (Aβ) 42. Aβ is produced via endoproteolysis by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which cleaves β-amyloid precursor protein at the extracellular domain, followed by cleavages by presenilin/γ-secretase. Aβ accumulation in the brain is thought to occur decades before disease onset, and pathological changes such as synaptic dysfunction and tau accumulation gradually proceed. Most candidates for disease-modifying therapy (DMT) for AD have targeted either inhibition of Aβ generation with secretase inhibitors or removal of produced and aggregated Aβ with anti-Aβ antibodies. None of them has been approved for clinical practice. Moreover, application of BACE inhibitors and γ-secretase inhibitors in several clinical studies caused paradoxical cognitive impairment. However, early AD patients treated with aducanumab, a monoclonal anti-Aβ antibody, showed a significant reduction in cognitive decline and its clinical use is awaiting approval by the FDA in 2020. In this review, we present a brief summary of DMTs that target Aβ and perspectives for future AD therapy.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10001_description_6": {"attribute_name": "内容種別", "attribute_value_mlt": [{"subitem_description": "Review Article", "subitem_description_language": "en", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "大阪河﨑リハビリテーション大学", "subitem_publisher_language": "ja"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2436-1097", "subitem_source_identifier_type": "PISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Shinji TAGAMI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "372", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masatoshi TAKEDA", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "314", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayasu OKOCHI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "376", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-08-10"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "C 1-012-019.pdf", "filesize": [{"value": "279.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 279400.0, "url": {"label": "C 1-012-019", "url": "https://kawasakigakuen.repo.nii.ac.jp/record/304/files/C 1-012-019.pdf"}, "version_id": "9e5d57e5-b225-4738-baa0-d84ca9af89a4"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Alzheimer disease", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "amyloid β-protein", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "γ-secretase inhibitors", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "BACE inhibitors", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "anti-Aβ antibodies", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "other", "resourceuri": "http://purl.org/coar/resource_type/c_1843"}]}, "item_title": "Clinical trials for Alzheimer disease and perspectives", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical trials for Alzheimer disease and perspectives", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "4", "path": ["34"], "permalink_uri": "https://kawasakigakuen.repo.nii.ac.jp/records/304", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-08-10"}, "publish_date": "2021-08-10", "publish_status": "0", "recid": "304", "relation": {}, "relation_version_is_last": true, "title": ["Clinical trials for Alzheimer disease and perspectives"], "weko_shared_id": -1}
Clinical trials for Alzheimer disease and perspectives
https://kawasakigakuen.repo.nii.ac.jp/records/304
https://kawasakigakuen.repo.nii.ac.jp/records/304c2a01a7f-4e8f-4cd0-9994-d5dae659560b
名前 / ファイル | ライセンス | アクション |
---|---|---|
C 1-012-019 (279.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-08-10 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Clinical trials for Alzheimer disease and perspectives | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Alzheimer disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | amyloid β-protein | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | γ-secretase inhibitors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | BACE inhibitors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | anti-Aβ antibodies | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_1843 | |||||
資源タイプ | other | |||||
内容種別 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Review Article | |||||
著者 |
Shinji TAGAMI
× Shinji TAGAMI× Masatoshi TAKEDA× Masayasu OKOCHI |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Alzheimer disease (AD) is the most common type of dementia and may account for 60 - 70% of dementia cases. Senile plaques are a hallmark of AD, and their major constituent is amyloid β-protein (Aβ) 42. Aβ is produced via endoproteolysis by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which cleaves β-amyloid precursor protein at the extracellular domain, followed by cleavages by presenilin/γ-secretase. Aβ accumulation in the brain is thought to occur decades before disease onset, and pathological changes such as synaptic dysfunction and tau accumulation gradually proceed. Most candidates for disease-modifying therapy (DMT) for AD have targeted either inhibition of Aβ generation with secretase inhibitors or removal of produced and aggregated Aβ with anti-Aβ antibodies. None of them has been approved for clinical practice. Moreover, application of BACE inhibitors and γ-secretase inhibitors in several clinical studies caused paradoxical cognitive impairment. However, early AD patients treated with aducanumab, a monoclonal anti-Aβ antibody, showed a significant reduction in cognitive decline and its clinical use is awaiting approval by the FDA in 2020. In this review, we present a brief summary of DMTs that target Aβ and perspectives for future AD therapy. | |||||
書誌情報 |
en : COGNITION & REHABILITATION 巻 1, 号 1, p. 12-19, 発行日 2020-12 |
|||||
出版者 | ||||||
言語 | ja | |||||
出版者 | 大阪河﨑リハビリテーション大学 | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 2436-1097 |